On March 27, 2024 Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, reported that it will present a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 5-10, 2024, in San Diego, California (Press release, Aqtual, MAR 27, 2024, View Source [SID1234641518]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have developed a plasma-based active chromatin capture method designed to capture both disease- and organ-specific molecular signals through a routine blood test," said Diana Abdueva, Ph.D., co-founder and CEO of Aqtual. "Our unique ability to analyze cell-free DNA derived from active chromatin enables comprehensive analysis of the epigenetic and transcriptomic landscape of both the tumor and immune components, providing novel insights that could help guide therapy selection and advance precision medicine."

Details of the poster presentation are as follows:

Poster Title: Detection of non-small cell lung and bladder cancer signatures in peripheral blood using a novel active chromatin capture assay
Date and Time: Tuesday, April 9, 9:00 AM – 12:30 PM
Session Category: Clinical Research
Session Title: Circulating Nucleic Acids 4
Location: Poster Section 40; Poster Board 15
Published Abstract Number: 5028